Aeterna Zentaris and FDA agree to SPA for Phase III endometrial cancer study
This article was originally published in Scrip
Canadian drug developer Aeterna Zentaris and the US FDA have agreed to a Special Protocol Assessment (SPA) for the Quebec City-based company's upcoming Phase III clinical trial for the doxorubicin-peptide conjugate AEZS-108 in the treatment of endometrial cancer.
You may also be interested in...
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.